Cargando…
Identification of a novel gene fusion in ALT positive osteosarcoma
The Alternative Lengthening of Telomeres (ALT) pathway stimulates telomere elongation and prevents cellular senescence in approximately 60% of osteosarcoma. While the precise mechanism underlying activation of the ALT pathway is unclear, mutations in the chromatin remodeling protein ATRX, histone ch...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132345/ https://www.ncbi.nlm.nih.gov/pubmed/30214690 http://dx.doi.org/10.18632/oncotarget.26029 |
_version_ | 1783354300372615168 |
---|---|
author | Mason-Osann, Emily Dai, Anqi Floro, Jess Lock, Ying Jie Reiss, Matthew Gali, Himabindu Matschulat, Adeline Labadorf, Adam Flynn, Rachel Litman |
author_facet | Mason-Osann, Emily Dai, Anqi Floro, Jess Lock, Ying Jie Reiss, Matthew Gali, Himabindu Matschulat, Adeline Labadorf, Adam Flynn, Rachel Litman |
author_sort | Mason-Osann, Emily |
collection | PubMed |
description | The Alternative Lengthening of Telomeres (ALT) pathway stimulates telomere elongation and prevents cellular senescence in approximately 60% of osteosarcoma. While the precise mechanism underlying activation of the ALT pathway is unclear, mutations in the chromatin remodeling protein ATRX, histone chaperone DAXX, and the histone variant H3.3 correlate with ALT status. ATRX and DAXX facilitate deposition of the histone variant H3.3 within heterochromatic regions suggesting that loss of ATRX, DAXX, and/or H3.3 lead to defects in the stability of telomeric heterochromatin. Genetic mutations in ATRX, DAXX, and H3.3 have been detected in ALT positive cancers, however, a subset of ALT samples show loss of ATRX or DAXX protein expression or localization without evidence of genetic alterations suggesting additional uncharacterized defects in ATRX/DAXX/H3.3 function. Here, using Next Generation Sequencing we identified a novel gene fusion event between DAXX and the kinesin motor protein, KIFC3, leading to the translation of a chimeric DAXX-KIFC3 fusion protein. Moreover, we demonstrate that the fusion of KIFC3 to DAXX causes defects in DAXX function likely promoting ALT activity. These data highlight a potentially unrecognized mechanism of DAXX inactivation in ALT positive osteosarcoma and provide rationale for thorough and comprehensive analyses of ATRX/DAXX/H3.3 proteins in ALT positive cancers. |
format | Online Article Text |
id | pubmed-6132345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-61323452018-09-13 Identification of a novel gene fusion in ALT positive osteosarcoma Mason-Osann, Emily Dai, Anqi Floro, Jess Lock, Ying Jie Reiss, Matthew Gali, Himabindu Matschulat, Adeline Labadorf, Adam Flynn, Rachel Litman Oncotarget Research Paper The Alternative Lengthening of Telomeres (ALT) pathway stimulates telomere elongation and prevents cellular senescence in approximately 60% of osteosarcoma. While the precise mechanism underlying activation of the ALT pathway is unclear, mutations in the chromatin remodeling protein ATRX, histone chaperone DAXX, and the histone variant H3.3 correlate with ALT status. ATRX and DAXX facilitate deposition of the histone variant H3.3 within heterochromatic regions suggesting that loss of ATRX, DAXX, and/or H3.3 lead to defects in the stability of telomeric heterochromatin. Genetic mutations in ATRX, DAXX, and H3.3 have been detected in ALT positive cancers, however, a subset of ALT samples show loss of ATRX or DAXX protein expression or localization without evidence of genetic alterations suggesting additional uncharacterized defects in ATRX/DAXX/H3.3 function. Here, using Next Generation Sequencing we identified a novel gene fusion event between DAXX and the kinesin motor protein, KIFC3, leading to the translation of a chimeric DAXX-KIFC3 fusion protein. Moreover, we demonstrate that the fusion of KIFC3 to DAXX causes defects in DAXX function likely promoting ALT activity. These data highlight a potentially unrecognized mechanism of DAXX inactivation in ALT positive osteosarcoma and provide rationale for thorough and comprehensive analyses of ATRX/DAXX/H3.3 proteins in ALT positive cancers. Impact Journals LLC 2018-08-28 /pmc/articles/PMC6132345/ /pubmed/30214690 http://dx.doi.org/10.18632/oncotarget.26029 Text en Copyright: © 2018 Mason-Osann et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Mason-Osann, Emily Dai, Anqi Floro, Jess Lock, Ying Jie Reiss, Matthew Gali, Himabindu Matschulat, Adeline Labadorf, Adam Flynn, Rachel Litman Identification of a novel gene fusion in ALT positive osteosarcoma |
title | Identification of a novel gene fusion in ALT positive osteosarcoma |
title_full | Identification of a novel gene fusion in ALT positive osteosarcoma |
title_fullStr | Identification of a novel gene fusion in ALT positive osteosarcoma |
title_full_unstemmed | Identification of a novel gene fusion in ALT positive osteosarcoma |
title_short | Identification of a novel gene fusion in ALT positive osteosarcoma |
title_sort | identification of a novel gene fusion in alt positive osteosarcoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132345/ https://www.ncbi.nlm.nih.gov/pubmed/30214690 http://dx.doi.org/10.18632/oncotarget.26029 |
work_keys_str_mv | AT masonosannemily identificationofanovelgenefusioninaltpositiveosteosarcoma AT daianqi identificationofanovelgenefusioninaltpositiveosteosarcoma AT florojess identificationofanovelgenefusioninaltpositiveosteosarcoma AT lockyingjie identificationofanovelgenefusioninaltpositiveosteosarcoma AT reissmatthew identificationofanovelgenefusioninaltpositiveosteosarcoma AT galihimabindu identificationofanovelgenefusioninaltpositiveosteosarcoma AT matschulatadeline identificationofanovelgenefusioninaltpositiveosteosarcoma AT labadorfadam identificationofanovelgenefusioninaltpositiveosteosarcoma AT flynnrachellitman identificationofanovelgenefusioninaltpositiveosteosarcoma |